Barrington Research Upgrades Haemonetics (HAE) to Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq end lower on semiconductor selloff as AI spending concerns mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Haemonetics Reports 1st Quarter Fiscal 2016 Revenue of $213 Million and Adjusted EPS of $0.35, Reaffirms Full Fiscal Year Guidance
July 27, 2015 6:00 AM EDTBRAINTREE, Mass., July 27, 2015 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) today reported first quarter fiscal 2016 revenue of $213.4 million, down 5%. Revenue declined 2% in constant currency in the quarter.Â
The Company reported a GAAP net loss of $0.3 million and a GAAP net loss per share of $0.01 in the quarter. Exclusive of transformation, restructuring and deal amortization expenses detailed below, adjusted net income was $18.0 million and adjusted earnings per share were $0.35, both down 9%.1  Â
1Q FISCAL 2016 STRATEGIC AND PRODUCT GROWTH HIGHLIGHTS
Strong constant... More